EZH2
ENSG00000106462
Target class
Epigenetic regulator
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- EZH2
- Gene name
- Enhancer of zeste 2 polycomb repressive complex 2 subunit
- Gene symbol
- EZH2
- Protein name
- Histone-lysine N-methyltransferase EZH2 (EC 2.1.1.356) (ENX-1) (Enhancer of zeste homolog 2) (Lysine N-methyltransferase 6)
- EZH1
- ENX-1
- KMT6
- KMT6A
- Gene biotype
- Protein coding
- Gene family
- Histone lysine methyltransferases|Myb/SANT domain containing|Polycomb repressive complex 2|SET domain containing
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 44
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 54.7
- Tissue specificity (Gini)
- 0.598
- Tissue specificity (tau)
- 0.914
- KEGG gene identifiers
- hsa:2146
- Protein interaction confidence
- 0.866306
- Protein interaction partners
- 209
- R-HSA-212300
- R-HSA-2559580
- R-HSA-3214841
- R-HSA-5617472
- R-HSA-8943724
- R-HSA-8953750
- R-HSA-9609690
- R-HSA-9710421
- R-HSA-9764725
- R-HSA-9909649
- End position
- 148884330
- Start position
- 148807257
- Chromosome
- 7
- Strand
- Reverse
- Nucleus . Note=Localizes to the inactive X chromosome in trophoblast stem cells. .
- Nucleoplasm
- PubMed 12101246
- PubMed 14532106
- PubMed 15231737
- PubMed 9584199
- Tissue specificity (tau)
- 0.914249
- Expression inequality (Gini)
- 0.598321
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 54.7
- Testis
- 41.42
- Esophagus - Mucosa
- 16.03
- Skin - Not Sun Exposed (Suprapubic)
- 14.82
- Skin - Sun Exposed (Lower leg)
- 14.69
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes54.7
- Testis41.42
- Esophagus - Mucosa16.03
- Skin - Not Sun Exposed (Suprapubic)14.82
- Skin - Sun Exposed (Lower leg)14.69
- Cells - Cultured fibroblasts12.15
- Spleen9.41
- Vagina9.17
- Small Intestine - Terminal Ileum9.09
- Brain - Cerebellar Hemisphere7.75
- Brain - Cerebellum7.44
- Colon - Transverse6.83
- Lung6.63
- Ovary5.53
- Cervix - Endocervix5.09
- Cervix - Ectocervix5.04
- Minor Salivary Gland4.85
- Nerve - Tibial4.44
- Uterus4.09
- Breast - Mammary Tissue3.86
- Adipose - Subcutaneous3.56
- Fallopian Tube3.36
- Stomach3.33
- Prostate3.32
- Kidney - Medulla3.32
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0006325
- GO:0006355
- GO:0008284
- GO:0010718
- GO:0030335
- GO:0031048
- GO:0031507
- GO:0031509
- GO:0042752
- GO:0043406
- GO:0043547
- GO:0045814
- GO:0045892
- GO:0048387
- GO:0071902
- GO:1902808
- GO:0000781
- GO:0000785
- GO:0000792
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0035098
- GO:0001222
- GO:0003682
- GO:0003723
- GO:0005515
- GO:0016279
- GO:0031490
- GO:0031491
- GO:0042054
- GO:0042393
- GO:0046976
- GO:0140938
- GO:0140951
- GO:1990841
Related records
Trials (124)
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
- A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
- A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
- A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
- A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Drugs (8)
- CPI-1205
- GSK2816126 Histone-lysine N-methyltransferase EZH2 inhibitor
- Mevrometostat
- Tazemetostat Histone-lysine N-methyltransferase EZH2 inhibitor
- Tazemetostat hydrobromide Histone-lysine N-methyltransferase EZH2 inhibitor
- Tulmimetostat
- Valemetostat
- Zeprumetostat